PAPER Lim YA, Rhein V, Baysang G, Meier F, Poljak A, Raftery MJ, Guilhaus M, Ittner LM, Eckert A, Götz J
SEARCH RESULTS
331209 RESULTS
PAPER Sozio P, D'Aurizio E, Iannitelli A, Cataldi A, Zara S, Cantalamessa F, Nasuti C, Di Stefano A
Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity.
Arch Pharm (Weinheim). 2010 Mar;343(3):133-42. PubMed: 20186865PAPER Guo J, Sun Z, Xiao S, Liu D, Jin G, Wang E, Zhou J
Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients.
Cell Res. 2009 Dec;19(12):1401-3. PubMed: 19949427PAPER Sherrod RA, Collins A, Wynn S, Gragg M
Dissecting dementia, depression, and drug effects in older adults.
J Psychosoc Nurs Ment Health Serv. 2010 Jan;48(1):39-47. PubMed: 20102132PAPER Ostrovskaia RU, Tsaplina AP, Vakhitova Iu, Salimgareeva MK, Iamidanov RS
[Effect of the novel nootropic and neuroprotective dipeptide noopept on the streptozotocin-induced model of sporadic Alzheimer disease in rats].
Eksp Klin Farmakol. 2010 Jan;73(1):2-6. PubMed: 20184279PAPER Hayashi Y, Ishida Y, Inoue T, Udagawa M, Takeuchi K, Yoshimuta H, Kiue K, Ninomiya Y, Kawano J, Sameshima T, Kawahara T, Goto I, Shudo K, Kurayama S, Nakamura J, Okahara K, Mitsuyama Y
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):541-5. PubMed: 20184936PAPER Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.
Ann Neurol. 2010 Jan;67(1):122-31. PubMed: 20186853PAPER Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y
Evidence in favor of Braak staging of Parkinson's disease.
Mov Disord. 2010;25 Suppl 1:S78-82. PubMed: 20187227SNX17
ANTIBODY polyclonal manufacturer Cat# ab67599 immunogen = full length protein, corresp. to aa1-470 of human SNX17 liquid, PBS, no preservative, protein A purified Sorting Nexin 17 IgG Protein Trafficking Abcam Mouse Human SNX17 http://alzforum.org/res/com/ant/defa
SNX16
ANTIBODY polyclonal manufacturer Cat# ab4151 immunogen = synthetic peptide: A T P Y V P V P M P I G N, corresp. to N- terminal aa 2-14 of human SNX16 liquid, TBS, BSA, azide Sorting Nexin 16, expected to recognise all three human isoforms IgG Protein Trafficking A
SNX15
ANTIBODY monoclonal manufacturer Cat# ab57107 immunogen = recombinant fragment corresp. to aa51-140 of human SNX15 liquid, PBS, no preservative, protein G purified Sorting Nexin 15 IgG<sub>3</sub>, κ Protein Trafficking Abcam Mouse Human SNX15 http://a
SNX15
ANTIBODY polyclonal manufacturer Cat# ab3990 immunogen = synthetic peptide: E E I L R L H L S Q L P P, corresp. to C-terminal aa330-342 of human SNX15 liquid, TBS, BSA, azide Sorting Nexin 15 recognises both isoforms IgG Protein Trafficking Abcam Goat Human SNX15
SNX12
ANTIBODY monoclonal manufacturer Cat# ab57129 immunogen = recombinant fragment, corresp. to aa53-159 of human SNX12 liquid, PBS, no preservative, protein G purified Sorting Nexin 12 IgG<sub>2a</sub>, κ Protein Trafficking Abcam Mouse Human SNX12 http:/
SNX11
ANTIBODY polyclonal manufacturer Cat# ab76816 immunogen = full length protein, corresp. to aa1-271 of human SNX11 liquid, PBS, no preservative, protein A purified Sorting Nexin 11 IgG Protein Trafficking Abcam Mouse Human SNX11 http://alzforum.org/res/com/ant/defa
SNX11
ANTIBODY polyclonal manufacturer Cat# ab67578 immunogen = recombinant full length protein (human SNX11) liquid, PBS, no preservative, protein A purified Sorting Nexin 11 IgG Protein Trafficking Abcam Mouse Human SNX11 http://alzforum.org/res/com/ant/default.asp?an
Current Filters
No filters selected